If there is a single trait that all game-changing stocks, regardless of their size or industry, share, it would be their outsized growth potential. This comes with the territory. An innovative company can benefit from being a disruptor by grabbing market share from established competition, contributing to the creation of new markets or accelerating the development of existing ones. In every case, if it’s successful, its innovative nature translates into faster-than-average growth. As the company in question grows its profits, its stock price responds in kind, appreciating faster than its peers. An accelerated growth means accelerated share-price appreciation, all else… Read More

If there is a single trait that all game-changing stocks, regardless of their size or industry, share, it would be their outsized growth potential. This comes with the territory. An innovative company can benefit from being a disruptor by grabbing market share from established competition, contributing to the creation of new markets or accelerating the development of existing ones. In every case, if it’s successful, its innovative nature translates into faster-than-average growth. As the company in question grows its profits, its stock price responds in kind, appreciating faster than its peers. An accelerated growth means accelerated share-price appreciation, all else equal. This growth potential can be especially rewarding in the world of small-cap stocks. While the risks are higher — a smaller company can grow faster but it can also falter easier as it often lacks the kind of resources needed to break through competition barriers — the rewards can be significant. This is why over at Game-Changing Stocks, we continue to emphasize growth companies. And this is why the stock screen I want to share with you today is about growth as well. The Screen: Small-Cap Growth Stocks I searched for companies with market capitalization of $1 billion… Read More

I recently finished remaking one of the rooms at my house into a personal office. After rearranging and unpacking boxes, I found myself thumbing through an old copy of “Beating the Street,” by Peter Lynch. It had been a while since I’ve read it, and I can faithfully report that most of what Lynch writes about still holds up in today’s market. I’m sure you’re familiar with Lynch, but his track record bears repeating. While at the helm of the Magellan Fund at Fidelity, Lynch delivered a 29.2% average annual return from 1977 to 1990. Probably the greatest mutual fund… Read More

I recently finished remaking one of the rooms at my house into a personal office. After rearranging and unpacking boxes, I found myself thumbing through an old copy of “Beating the Street,” by Peter Lynch. It had been a while since I’ve read it, and I can faithfully report that most of what Lynch writes about still holds up in today’s market. I’m sure you’re familiar with Lynch, but his track record bears repeating. While at the helm of the Magellan Fund at Fidelity, Lynch delivered a 29.2% average annual return from 1977 to 1990. Probably the greatest mutual fund manager of all time, we have Lynch to thank for popular investing phrases like “invest in what you know,” “10-bagger” (a stock that gains 1,000%), “GARP” (growth at a reasonable price), and more. But what you might not know about Lynch is the story behind his exit from the Magellan Fund… —Recommended Link— The Single Best Group of Stocks to Buy NOW Since 1926, one collection of stocks has accounted for HALF of the S&P’s return — through every market environment imaginable. If you don’t have these picks in your own portfolio, you could be missing out on the… Read More

Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits… Read More

Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits We’ve unleashed it again — our annual Game-Changing Predictions report, filled cover-to-cover with a dozen potentially life-changing picks for 2019. And to mark this 10th anniversary edition, we’re doing something a little different… In addition to the full write up on each prediction (complete with the tickers), the first 250 readers to claim their copy will get instant access to 2 additional “bonus picks” that are positioned to bring home double… even triple-digit gains in 2019. If the thought of an extra $1,543… $2,184… even $4,200 each month in cash sounds good to you, click here now to see if… Read More

It’s one of the few holdings in my Daily Paycheck portfolio that has lost ground in 2019… But there’s a good reason. On January 3, Bristol Myers Squibb (NYSE: BMY) unveiled plans to buy Celgene (Nasdaq: CELG) in a blockbuster $74 billion transaction.  Acquirers typically fall when these mega-deals are announced, while shares of the target bolt higher. True to form, BMY slid 14% on the news, while CELG jumped 25%.  Despite the drop, my subscribers and I are still in the black on this one. But is this a good deal? And is BMY worth owning today?  First, let’s… Read More

It’s one of the few holdings in my Daily Paycheck portfolio that has lost ground in 2019… But there’s a good reason. On January 3, Bristol Myers Squibb (NYSE: BMY) unveiled plans to buy Celgene (Nasdaq: CELG) in a blockbuster $74 billion transaction.  Acquirers typically fall when these mega-deals are announced, while shares of the target bolt higher. True to form, BMY slid 14% on the news, while CELG jumped 25%.  Despite the drop, my subscribers and I are still in the black on this one. But is this a good deal? And is BMY worth owning today?  First, let’s get some of the specifics out of the way. Bristol Myers is offering one share of BMY and $50 cash for each share of CELG. There is also the possibility of additional cash remuneration for Celgene investors later down the line (known as a contingent value right, or CVR) if three drugs in the firm’s pipeline eventually gain regulatory approval.  Based on BMY’s share price at the time of the announcement, the bid (excluding CVRs) works out to a little more than $102 per share. That’s a healthy premium of 53% above where CELG closed the day before the announcement. … Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size… Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size for legal pot in Canada. Retail stores are still opening; Ontario, the country’s largest state, still hasn’t opened any retail stores (in this state, sales are still limited to online orders). Further, the demand was so strong that a number of stores ran out of product. Canopy Growth: Best In The Business In the three months since I first added Canada’s Canopy Growth Corp. (NYSE: CGC) to the our Fast-Track Millionaire portfolio, the stock has handily outperformed its closest peer, Tilray (Nasdaq: TLRY). While TILR has lost nearly 30% of its value over these three months, CGC has appreciated by more… Read More

Since December 24, when the S&P 500 registered its lowest mark of 2018 (and a near 20% pullback from its September highs) we’ve seen a robust rebound. The index has rallied more than 12% since then.  I don’t know whether we’re out of the woods just yet… but between a couple of bullish indicators that I’ll discuss below, and my Maximum Profit system signaling four new buys last week, I’d say that the outlook at the moment is positive.  —Recommended Link— What would YOU do with an extra $3,080 every month for the rest of your life? Never worry… Read More

Since December 24, when the S&P 500 registered its lowest mark of 2018 (and a near 20% pullback from its September highs) we’ve seen a robust rebound. The index has rallied more than 12% since then.  I don’t know whether we’re out of the woods just yet… but between a couple of bullish indicators that I’ll discuss below, and my Maximum Profit system signaling four new buys last week, I’d say that the outlook at the moment is positive.  —Recommended Link— What would YOU do with an extra $3,080 every month for the rest of your life? Never worry about cash again. Be free to live how YOU want… go on a lavish vacation… or build up a college fund for the grandkids–it’s up to you.  Get your share here… Indicator #1 The first bullish indicator is one that I touched on previously, and that’s the Advance-Decline Line (AD Line). This is a breadth indicator that shows us how many stocks in the underlying index — the NYSE Composite Index in this case — are advancing and how many are declining. The purpose of looking at a breadth indicator is to gauge market sentiment, whether it’s leaning… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match or exceed the breakneck activity of 2018 when 190 companies went public.  But this does not mean we cannot learn or benefit from the IPO market — these 190 recently-minted public companies offer a lot of new ideas and fresh profit opportunities.  Because of the sheer number of these fledgling companies, I had to first narrow down my area of interest. At this time, I’m focusing on the consumer discretionary sector. With numerous innovations hitting the consumer market, I thought it would be interesting to see how well these companies are being received by the investing public.  Hence, today’s… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take care of tissue, organs, and biochemistry. Blobel’s mentor at Rockefeller University, Dr. George Palade, was a wizard with electron microscopes — his work earned him the Nobel in 1974. Blobel figured out that there are about a quadrillion cells in the human body, each containing about a billion protein molecules that are spun out of little cavities known as endoplasmic reticula. These proteins are all guarded by special membranes. He and a colleague hypothesized that each of these proteins also contains proteins that act as airport luggage tags, as his obituary in the Times put it. It turns out this… Read More

For biotech investors, the year has started with a bang. First, it was Bristol-Myers Squibb’s (NYSE: BMY) enormous $74 billion bid for Celgene (Nasdaq: CELG), one of the largest biotech companies in the world. Right on its heels came a smaller but still significant move — the announcement on Jan. 7 of Eli Lilly’s (NYSE: LLY) intended $8 billion acquisition of Loxo Oncology (Nasdaq: LOXO). —Recommended Link— Market Rally Forecast For The Next 3 Days Did you know the stock market rallied during every government shutdown over the past 25 years? In fact, this time,… Read More

For biotech investors, the year has started with a bang. First, it was Bristol-Myers Squibb’s (NYSE: BMY) enormous $74 billion bid for Celgene (Nasdaq: CELG), one of the largest biotech companies in the world. Right on its heels came a smaller but still significant move — the announcement on Jan. 7 of Eli Lilly’s (NYSE: LLY) intended $8 billion acquisition of Loxo Oncology (Nasdaq: LOXO). —Recommended Link— Market Rally Forecast For The Next 3 Days Did you know the stock market rallied during every government shutdown over the past 25 years? In fact, this time, it’s already up 10%… and still going. There’s a trade that exploits this situation exceptionally well, and you can take advantage of it over the next 3 days. You can find the full details here. I think we can expect even more deals as the year progresses. And that, of course, is potentially great news for investors… There are several industry-specific factors making it imperative that the flow of deals continues. For several years now, large pharma has been facing a crisis of sorts. The business model of drug companies has long been based on having… Read More

This may be the year we see retail roar back. If you remove the last quarter of 2018, the sector posted strong performance numbers. Surging behind low unemployment, climbing consumer confidence, and a better-than-expected holiday season, retail hit fresh highs in 2018. Then, along with the rest of the market, the bottom fell out in December with stocks plunging to their worse end-of-year performance since the Great Depression. —Recommended Link— Wall Street Won’t Tell You About This… But We Just Uncovered A Bombshell… I’ve created an in-depth report for this opportunity and it covers what I believe is the… Read More

This may be the year we see retail roar back. If you remove the last quarter of 2018, the sector posted strong performance numbers. Surging behind low unemployment, climbing consumer confidence, and a better-than-expected holiday season, retail hit fresh highs in 2018. Then, along with the rest of the market, the bottom fell out in December with stocks plunging to their worse end-of-year performance since the Great Depression. —Recommended Link— Wall Street Won’t Tell You About This… But We Just Uncovered A Bombshell… I’ve created an in-depth report for this opportunity and it covers what I believe is the biggest investment opportunity we’ll see in our lifetime… It will change the concept of what it means to be human, as we see major diseases eradicated… and as our life expectancy reaches 120 years. I’ve been tracking this development for seven years… At the same time, consumer confidence remains high, oil prices low, and employment solid in the face of the retail rout. Add in the abating Chinese tariff pressures and a bullish picture is painted for retail and the overall market in 2019. #-ad_banner-#Strategically buying dips is a time-honored way to profit from the stock market. December beat retail… Read More